- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00213031
Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide
A Randomized, Placebo-controlled, Double-blind Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of PC-515 (Lambda Carrageenan) for Vaginal Use as a Possible Microbicide
The primary aims of the study were to assess the safety and acceptability of PC-515 when applied vaginally at least three times weekly for 12 months. Secondary aims were to gather preliminary data on Carraguard's effectiveness in preventing male-to-female transmission of HIV, and other STIs.
The hypothesis was that Carraguard would cause little or no significant irritation, including lesions; and that women would find Carraguard acceptable. The study was not powered to determine effectiveness, but based on safety, acceptability and feasibility parameters, the outcome of the Phase 2 trial would enable a decision whether or not to proceed to a Phase 3 trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Carraguard™ (PC-515), the Population Council's lead candidate microbicide, was tested in a triple-masked, randomized, placebo-controlled trial fielded in one site in Chiang Rai, northern Thailand. The primary aims of the study were to assess Carraguard's safety (toxicity) - including signs of local irritation, such as itching or burning; changes in vaginal flora; and incidence of abnormal external genital, vaginal, and cervical findings - when applied vaginally for 12 months; to evaluate acceptability; to assess feasibility of conducting a large scale microbicide trial in a non-sex worker population; to gauge women's reactions to a non-contraceptive microbicide; and to explore microbicide use dynamics in a Thai population.
Secondary aims were to investigate HIV infections averted (preliminary indications); other sexually transmitted infections averted - including C. trachomatis, N. gonorrhoeae, T. vaginalis, and T. pallidum (preliminary indications); and effect on cervical cytology.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Chiang Rai, Thailand, 57001
- Chiang Rai Health Club
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- In good health as determined by medical history, physical examination and results of laboratory screening tests
- Aged 18 years or older
- Resident in the area for at least one year and planning to stay for at least 12 months
- HIV-seronegative at baseline
- Willing and able to comply with the study protocol (including being tested for HIV, learning the results, and undergoing clinical evaluations)
- Able to achieve a score of 80% or better on true-false test of key study concepts
- Able to give informed consent
Exclusion Criteria:
- Pregnant or desire to become pregnant at time of study participation
- Delivered or aborted a pregnancy within the six weeks prior to screening
- Male sex partner known at enrollment to be HIV positive
- History of surgery on external genitalia, vagina or cervix in the six weeks prior to screening
- Recent history of non-menstrual vaginal bleeding with intercourse
- Clinically detectable genital abnormality (including presence of warts, or a structural or congenital abnormality)
- Clinical suspicion of a reproductive tract infection (RTI), defined as the presence of a genital ulcer visible to the naked eye, an abnormal vaginal discharge or purulent cervicitis, or untreated positive STD result (Women could be enrolled after treatment of identified RTI. Women with persistent genital epithelial disruption, i.e., ulcer, abrasion or fissure, were not eligible.
- Women with other persistent abnormal signs, such as vaginal or cervical discharge, despite treatment of identified RTI, were eligible)
- Abnormal Pap smear (Class II or above)
- History of sensitivity/allergy to latex
- Concurrent participation in another trial of a vaginal product
- Injection of recreational drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety: Genital exam & interview for symptoms after 14 days & monthly thereafter; colposcopy done throughout trial at clinicians' discretion; monthly testing to detect changes in vagina flora.
|
Compliance: collection of applicators and interview(monthly)
|
Acceptability: interview (quarterly)
|
Secondary Outcome Measures
Outcome Measure |
---|
Preliminary effectiveness: Swabs taken to test for sexually transmitted infections - gonorrhea, chlamydia, trichomoniasis and for genital ulcer disease, if ulceration was detected; blood drawn for syphilis and HIV testing and for HSV-2 Pap smear to det
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Janneke HMM van de Wijgert, Ph.D., Population Council
Study record dates
Study Major Dates
Study Start (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Virus Diseases
- Infections
- Communicable Diseases
- Sexually Transmitted Diseases
- DNA Virus Infections
- Gram-Negative Bacterial Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Parasitic Diseases
- Protozoan Infections
- Skin Diseases, Infectious
- Skin Diseases, Viral
- Herpesviridae Infections
- Vaginal Diseases
- Neisseriaceae Infections
- Sexually Transmitted Diseases, Bacterial
- Spirochaetales Infections
- Treponemal Infections
- Trichomonas Infections
- Vaginitis
- Gonorrhea
- Herpes Simplex
- Syphilis
- Trichomonas Vaginitis
Other Study ID Numbers
- Population Council #271
- CDC & Prevention #2485
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHIV Infections | HIV SeronegativityUnited States, Puerto Rico
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
Clinical Trials on Carraguard (PC-515)
-
Population CouncilCenters for Disease Control and Prevention; Ministry of Health, Thailand; National... and other collaboratorsCompleted
-
Population CouncilNational Institute of Allergy and Infectious Diseases (NIAID); United States... and other collaboratorsCompletedHIV Infections | Syphilis | Trichomonas Vaginitis | Chlamydia Trachomatis | Neisseria GonorrhoeaeSouth Africa
-
Population CouncilUnited States Agency for International Development (USAID); Bill and Melinda...CompletedHIV Infections | Sexually Transmitted Diseases | AIDS | HIV SeroconversionSouth Africa
-
Population CouncilMedical Research Council; Centers for Disease Control and PreventionCompleted
-
Population CouncilBill and Melinda Gates Foundation; Centers for Disease Control and Prevention; Ministry of Health, Thailand and other collaboratorsCompletedHIV Infections | Syphilis | Trichomonas Vaginitis | Chlamydia Trachomatis | Nesseria GonorrheaThailand
-
TretheraRecruitingOncology | Solid Tumor, AdultUnited States
-
University Hospital, Basel, SwitzerlandCompletedHeart Failure; With DecompensationSwitzerland
-
KU LeuvenAmsterdam UMC, location VUmc; Agentschap voor Innovatie door Wetenschap en... and other collaboratorsUnknownNursing Home Residents With Palliative Care NeedsBelgium
-
Boehringer IngelheimCompleted
-
Massachusetts General HospitalNational Cancer Institute (NCI)Completed